Research To Practice | Oncology Videos

Featuring perspectives from Dr Eileen O'Reilly and Dr Zev Wainberg, including the following topics: Introduction (0:00) Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Cancer (11:42) Ongoing Clinical Trials (31:33) Current and Future Role of Biomarker-Based Decision-Making in Metastatic Pancreatic Cancer (41:04) CME information and select publications

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 2: Key Data Sets with Bispecific Antibodies in Diffuse Large B-Cell Lymphoma and Other Non-Hodgkin Lymphoma Subtypes — Martin Hutchings, MD, PhD CME information and select publications

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 1: Role of Bispecific Antibody Therapy in Follicular Lymphoma — Loretta J Nastoupil, MD CME information and select publications

Featuring perspectives from Professor Martin Hutchings and Dr Loretta J Nastoupil, including the following topics: Introduction (0:00) Follicular Lymphoma (2:42) Diffuse Large B-Cell Lymphoma (35:41) CME information and select publications

Featuring perspectives from Prof Georgina Long, including the following topics: Introduction: (0:00) Journal Club with Prof Long – Part 1 (7:56) Case: A man in his mid 70s presents with bilateral painfully inflamed red ears and is diagnosed with BRAF V600E-mutated metastatic melanoma — Joanna Metzner-Sadurski, MD (27:19) Case: A man in his early 70s with past medical history of diabetes, hypertension, chronic obstructive pulmonary disease and several skin cancers is diagnosed with BRAF wild-type Stage IIIA melanoma — Helen H Moon, MD (32:52) Case: A man in his late 50s with past medical history of Stage III melanoma and multiple metastatic recurrences responds to single-agent pembrolizumab — Warren S Brenner, MD (43:02) Case: A man in his mid 70s develops metastatic recurrence of melanoma after relatlimab/nivolumab on clinical trial and pembrolizumab therapy for Stage III BRAF V600K-mutated melanoma — Priya Rudolph, MD (50:48) Case: A woman in her mid 30s with a personal and family history of melanoma develops multiple axillary nodes with BRAF-mutated melanoma without a primary lesion — Dr Moon (58:18) CME information and select publications

Featuring perspectives from Dr Corey J Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands, including the following topics: Optimal use of front-line immune checkpoint inhibition for metastatic non-small cell lung cancer (NSCLC) (00:00) Case: A man in his late 60s with NSCLC, no actionable mutations, PD-L1 20%, who received second-line datopotamab deruxtecan as part of a clinical trial (12:29) Case: A man in his early 70s with metastatic NSCLC, PD-L1 30%, who received first-line chemotherapy with pembrolizumab followed by maintenance pembrolizumab and second-line ramucirumab/pembrolizumab after disease progression (29:29) Case: A man in his mid 60s, PD-L1 60% and no actionable mutations who received first-line single-agent pembrolizumab followed by the addition of chemotherapy and chemotherapy/immunotherapy maintenance for NSCLC (40:23) Case: A woman in her late 60s with NSCLC, PD-L1 60%, with complete response in the liver and lung to second-line tumor treating fields with atezolizumab (57:18) Current Management of NSCLC After Disease Progression on Anti-PD-1/PD-L1-Containing Regimens — Dr Langer (1:10:48) Potential Role of Novel Immunotherapy-Based Combination Strategies in Progressive Advanced NSCLC – Dr Reckamp (1:30:14) TROP2 and Novel Antibody Drug Conjugates Under Evaluation in NSCLC – Dr Sands (1:53:36) Other Promising Therapeutic Strategies for Patients with Progressive Metastatic NSCLC – Dr Leal (2:18:58) CME information and select publications

Featuring perspectives from Dr Ghassan Abou-Alfa and Dr Daneng Li, including the following topics: Introduction: Etiology of Hepatocellular Carcinoma (HCC) and IO Response (0:00) First-Line Therapy for Advanced HCC — Dr Abou-Alfa (17:42) Second- and Later-Line Therapy for Advanced HCC; Emerging Considerations for Patients with Resectable HCC — Dr Li (38:12) CME information and select publications

Inside the Issue: Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer | Faculty Presentation: Treatment Intensification for Patients with Locally Advanced and Biochemically Recurrent Prostate Cancer — Neal D Shore, MD CME information and select publications

Featuring perspectives from Dr Neal D Shore and Dr Mary-Ellen Taplin, including the following topics: Introduction (0:00) Key Data Sets (8:18) Faculty Survey (39:50) CME information and select publications

Featuring perspectives from Dr Michael Wang, including the following topics: Algorithm for observation versus initiation of therapy for newly diagnosed mantle cell lymphoma (MCL) (0:00) First- and second-line therapy approaches for MCL (7:26) Case: A 45-year-old woman with relapsed MCL receiving acalabrutinib who develops severe headaches (10:21) Current role of ibrutinib in the treatment of MCL; use of single-agent venetoclax and of zanubrutinib in the treatment algorithm (14:59) Case: A 68-year-old man presenting with an enlarged spleen, no lymphadenopathy and a white blood cell count of 300,000 is diagnosed with MCL (17:48) Case: A 71-year-old man with multiregimen-relapsed, nodular type MCL presents with lymphadenopathy and a 3-cm tumor near the mediastinum (22:38) Patient selection for chimeric antigen receptor T-cell therapy (25:59) Novel and investigational therapeutic approaches for MCL (30:11) Treatment approaches for other histological variants of MCL (39:00) CME information and select publications